Fisker Inc.

Fisker Inc. (NYSE: FSR) is developing a technology-enabled, asset-light automotive business model that it thinks will be among the first of its kind and in line with the automotive industry's future condition. The company is an e-mobility service provider using environmentally friendly automobiles.

Key Highlights:

• The company has not yet commenced its core commercial operations, which will focus on the production and marketing of its automobiles.
• Net loss for Q3FY21 increased to USD 109.84 million from USD 39.66 million reported in Q3FY20, attributable to high operating expenditure.
• The company's gross margin fell to -6.7% in Q3FY21, down from 48.1% in Q2FY21.
• Stock is currently trading below its crucial short-term (50-day) and long-term (200-day) DMA support levels, indicating a bearish trend.
• Stock is leaning towards the lower end of the 52-week range of USD 9.61 – USD 31.96.
• FSR stock price has declined 25.50% in the past month.

Technical Price Chart (as of January 20, 2022). Analysis by Kalkine Group

Conclusion: Considering significant losses, lack of visibility in topline performance, macroeconomic factors, and technical indicators, we recommend an 'Avoid' rating on the stock at the closing price of USD 12.71, down 5.36% as of January 20, 2022.

*The reference data in this report has been partly sourced from REFINITIV.

Vaxart, Inc.

Vaxart, Inc. (NASDAQ: VXRT) is a biotechnology company at the clinical stage. Its primary goal is to create oral recombinant vaccines that protect against a broad spectrum of infectious diseases. Its tablet pipeline includes drugs for the treatment of Coronavirus, Norovirus, Seasonal Influenza, RSV (respiratory syncytial virus), and HPV (Human papillomavirus).

Key Highlights:

• In Q3FY21 (ended September 30, 2021), the company reported total revenue of USD 0.20 million, compared to USD 0.27 million in Q3FY20.
• The net loss for Q3FY21 increased to USD 17.58 million, up from USD 8.09 million in Q3FY20.
• The company is operating at a cash conversion cycle of 68 days in Q3FY21 vs. an industry median of 30 days
• Stock is currently trading below its crucial short-term (50-day) and long-term (200-day) DMA support levels, indicating a bearish trend.
• Stock is leaning towards the lower end of the 52-week range of USD 4.86 – USD 24.90.
• VXRT stock price has declined 39.16% in the past six months.

Technical Price Chart (as of January 20, 2022). Analysis by Kalkine Group

Conclusion: Considering the company's dismal topline performance, operating with weak fundamentals, gloomy outlook, and technical indicators, we recommend an 'Avoid' rating on the stock at the closing price of USD 5.05, down 3.63% as of January 20, 2022.

*The reference data in this report has been partly sourced from REFINITIV. 

Disclaimer

The advice given by Kalkine Canada Advisory Services Inc. and provided on this website is general information only and it does not take into account your investment objectives, financial situation and the particular needs of any particular person. You should therefore consider whether the advice is appropriate to your investment objectives, financial situation and needs before acting upon it. You should seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) as necessary before acting on any advice. Not all investments are appropriate for all people. The website www.kalkine.ca is published by Kalkine Canada Advisory Services Inc. The link to our Terms & Conditions has been provided please go through them. On the date of publishing this report (mentioned on the website), employees and/or associates of Kalkine do not hold positions in any of the stocks covered on the website. These stocks can change any time and readers of the reports should not consider these stocks as advice or recommendations later.